NCT05398510View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions
IgA Nephropathy
Interventions
DRUG

SHR-2010 injection

Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.

DRUG

SHR-2010 injection placebo

Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.

Trial Locations (1)

266555

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY